Document is current
Any future updates will be listed below
-
Authors
Yan, Jinyuan https://orcid.org/0000-0003-2046-5625
Liao, Chen https://orcid.org/0000-0001-8474-1196
Taylor, Bradford P.
Fontana, Emily
Amoretti, Luigi A.
Wright, Roberta J.
Littmann, Eric R.
Dai, Anqi
Waters, Nicholas https://orcid.org/0000-0002-9035-2143
Peled, Jonathan U. https://orcid.org/0000-0002-4029-7625
Taur, Ying
Perales, Miguel-Angel https://orcid.org/0000-0002-5910-4571
Siranosian, Benjamin A.
Bhatt, Ami S.
van den Brink, Marcel R. M. https://orcid.org/0000-0003-0696-4401
Pamer, Eric G. https://orcid.org/0000-0002-6755-9904
Schluter, Jonas https://orcid.org/0000-0002-6214-9367
Xavier, Joao B. https://orcid.org/0000-0003-3592-1689
-
Funding
Funding for this research was provided by:
Foundation for the National Institutes of Health (R01 AI137269, U01 AI124275, U01 AI124275, R01 AI137269)
- License Information
-
More Information
Article History
Received: 19 October 2021
Accepted: 21 February 2022
First Online: 18 May 2022
Competing interests
: M.R.M.v.d.B. received financial support from Seres Therapeutics. J.U.P. reports research funding, intellectual property fees, and travel reimbursement from Seres Therapeutics, and consulting fees from DaVolterra, CSL Behring, and from MaaT Pharma. He has filed intellectual property applications related to the microbiome (reference numbers #62/843,849, #62/977,908, and #15/756,845). M.-A.P/ has received honoraria from AbbVie, Bellicum, Bristol-Myers Squibb, Incyte, Merck, Novartis, Nektar Therapeutics, and Takeda; has received research support for clinical trials from Incyte, Kite (Gilead) and Miltenyi Biotec; and serves on data and safety monitoring boards for Servier and Medigene and scientific advisory boards for MolMed and NexImmune.
